Moreover, synthetic lethal strategies have the unique benefit of enabling targeting of loss-of-function alterations, which would be relevant for cancer types frequently exhibiting reduced expression of E3 ubiquitin ligases (e.g., RNF20 or RNF40) or DUBs (e.g., BAP1 or USP22). This evidence concerns the gene RNF40 and cancer.